Chalcogen Attached Indirectly To The Five-membered Hetero Ring By Acyclic Nonionic Bonding Patents (Class 548/551)
-
Patent number: 6872745Abstract: Compounds of the formula: where the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also described.Type: GrantFiled: May 12, 2003Date of Patent: March 29, 2005Assignee: Agouron Pharmaceuticals, Inc.Inventors: Theodore O. Johnson, Jr., Ye Hua, Hiep T. Luu, Peter S. Dragovich
-
Patent number: 6849657Abstract: This invention relates to 8-aza prostanoid analogs which are generally EP4 receptor agonists and are represented by Formula I: wherein Q, B, X, J, Z, A and R1-R6 are as defined, their synthesis and use for treatment of osteoporosis and increasing bone density.Type: GrantFiled: July 16, 2002Date of Patent: February 1, 2005Assignee: Syntex (U.S.A.) LLCInventors: Todd Richard Elworthy, Michael Garret Roepel, David Bernard Smith
-
Patent number: 6831039Abstract: The invention relates to 3-(heterocyclyl)-substituted benzoylpyrazois of formula (I), wherein the variables have the following meanings: X is O, NH or N-alkyl; R1 is alkyl; R2, R3, R4, R5 are hydrogen, alkyl or alkyl halide; R6 is halogen, nitro, alkyl halide, alkoxy, halogenalkoxy, alkylthio, halogenalkylthio, alkylsulfonyl or halogenalkylsulfonyl; R7 is hydroxy, alkoxy, alkenyloxy, alkylsulfonyloxy, alkylcarboyloxy, alkylthiocarbonyloxy, phenylsulfonyloxy or phenylcarbonyloxy, and the phenyl radical can be substituted; R8, R9 are alkyl; R10 is hydrogen or alkyl; and R11 is hydrogen or alkyl; and to their agriculturally useable salts. The invention also relates to intermediate products and methods for producing the inventive compounds and to the use of these compounds or products containing them for combating undesirable plants.Type: GrantFiled: May 21, 2001Date of Patent: December 14, 2004Assignee: BASF AktiengesellschaftInventors: Ulf Neidlein, Norbert Götz, Ernst Baumann, Wolfgang von Deyn, Steffen Kudis, Klaus Langemann, Guido Mayer, Ulf Misslitz, Matthias Witschel, Martina Otten, Karl-Otto Westphalen, Helmut Walter
-
Patent number: 6812240Abstract: The present invention provides a compound represented by the general formula I; wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.Type: GrantFiled: January 26, 2004Date of Patent: November 2, 2004Assignee: Allergan, Inc.Inventors: David W. Old, Thang D. Dinh, Robert M. Burk
-
Publication number: 20040204476Abstract: The present invention relates to an improved process for the preparation of (S)-(−)-&agr;-ethyl-2-oxo-1-pyrrolidine acetamide and analogues thereof. The invention also relates to compounds of the general formula (6) wherein R1 is methyl or ethyl; and R2 is C?2#19 1-C?4#191 alkyl, C?2#191 -C?4#191 alkenyl or C?2#191-C?4#191 alkynyl, optionally substituted by one or more halogen, and their preparation processes.Type: ApplicationFiled: February 10, 2004Publication date: October 14, 2004Inventors: Celal Ates, John Surtees, Anne-Catherine Burteau, Violeta Marmon, Emile Cavoy
-
Publication number: 20040204590Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.Type: ApplicationFiled: April 22, 2004Publication date: October 14, 2004Inventors: Miller J. Ogidigben, Robert N Young, Kathleen M Metters, Deborah M Slipetz
-
Patent number: 6784167Abstract: 17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S; R1 represents —H or optionally substituted —(C1-C4)alkyl; n represents 0 or an integer of 1-3; and R2 represents any of a variety of substituents on ring A. R4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR5, or —SR5, and R5 represents —H, optionally substituted —(C1-C4)alkyl, optionally substituted -phenyl, optionally substituted —(C1-C4)alkyl-phenyl, or optionally substituted —(C1-C4)acyl. R6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl.Type: GrantFiled: September 28, 2001Date of Patent: August 31, 2004Assignee: Bayer Pharmaceuticals CorporationInventors: Jill E. Wood, Jeremy L. Baryza, Catherine R. Brennan, Soongyu Choi, James H. Cook, Brian R. Dixon, Paul P. Ehrlich, David E. Gunn, Ian McAlexander, Peiying Liu, Derek B. Lowe, Anikó M. Redman, William J. Scott, Yamin Wang
-
Patent number: 6770763Abstract: A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below from appropriate pyrrolidinones is described. These compounds are useful as intermediates for MMP and TACE inhibitors.Type: GrantFiled: March 14, 2003Date of Patent: August 3, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Nicholas A. Magnus, Pasquale N. Confalone, Scott A. Savage, Matthew Yates, Robert E. Waltermir, David J. Meloni, Silvio Campagna
-
Publication number: 20040138201Abstract: This invention relates to novel lactams of Formula (I): 1Type: ApplicationFiled: October 14, 2003Publication date: July 15, 2004Inventors: Qi Han, Hong Liu, Richard E. Olson, Michael G. Yang
-
Publication number: 20040106593Abstract: The present invention relates to highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using therefor. The invention involves a multi-step synthesis to produce the lactam compounds. In one step of the reaction sequence, asymmetric hydrogenation of a lactam-enamide was performed to produce an intermediate that can ultimately be converted to a series of pharmaceutical compounds. The invention also contemplates the in situ synthesis of an intermediate of the multi-step synthesis, which provides economic advantages to the overall synthesis of the lactam compounds.Type: ApplicationFiled: November 25, 2003Publication date: June 3, 2004Inventors: Neil Warren Boaz, Sheryl Davis Debenham
-
Patent number: 6734201Abstract: The present invention provides a compound represented by the general formula I; wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.Type: GrantFiled: June 2, 2003Date of Patent: May 11, 2004Assignee: Allergan, Inc.Inventors: David W. Old, Thang D. Dinh, Robert M. Burk
-
Patent number: 6734206Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein X, Y, Z, D and R3 are as defined in the specification.Type: GrantFiled: June 2, 2003Date of Patent: May 11, 2004Assignee: Allergan, Inc.Inventors: David W. Old, Thang D. Dinh, Robert M. Burk
-
Patent number: 6686477Abstract: The present invention relates to highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using therefor. The invention involves a multi-step synthesis to produce the lactam compounds. In one step of the reaction sequence, asymmetric hydrogenation of a lactam-enamide was performed to produce an intermediate that can ultimately be converted to a series of pharmaceutical compounds. The invention also contemplates the in situ synthesis of an intermediate of the multi-step synthesis, which provides economic advantages to the overall synthesis of the lactam compounds.Type: GrantFiled: September 20, 2001Date of Patent: February 3, 2004Assignee: Eastman Chemical CompanyInventors: Neil Warren Boaz, Sheryl Davis Debenham
-
Patent number: 6642266Abstract: This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: wherein the variables are as defined in the specification.Type: GrantFiled: November 16, 2001Date of Patent: November 4, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, HuaZhu Ke, Bruce A. Lefker, David D. Thompson
-
Patent number: 6613795Abstract: Disclosed are enantiomerically pure cyclic aminoalcohol esters of arylcycloalkylhydroxycarboxylic acids with at least 90% enantiomeric excess of the (3R,2′R), (3S,2′R), (3R,2′S), or (3S,2′S) configured enantiomer.Type: GrantFiled: July 9, 2001Date of Patent: September 2, 2003Inventors: Christian Noe, Ernst Mutschler, Günter Lambrecht, Michael Elgert, Sittah Czeche, Magali Waelbroeck
-
Patent number: 6610730Abstract: Compounds of the formula: where the formula variables are as defined in the disclosure, advantageously inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with one or more picornaviruses, such as RVP. Intermediates and synthetic methods for preparing such compounds are also described.Type: GrantFiled: April 12, 2001Date of Patent: August 26, 2003Assignee: Agouron Pharmaceuticals, Inc.Inventors: Theodore O. Johnson Jr., Ye Hua, Hiep T. Luu, Peter S. Dragovich
-
Publication number: 20030114516Abstract: Novel amides and imides are inhibitors of tumor necrosis factor&agr; and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions.Type: ApplicationFiled: December 11, 2002Publication date: June 19, 2003Inventors: George W. Muller, Mary Shire
-
Patent number: 6552067Abstract: This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.Type: GrantFiled: November 21, 2001Date of Patent: April 22, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Bruce A. Lefker
-
Patent number: 6512120Abstract: This invention is directed to methods of synthesizing densely functionalized pyrrolidine compounds through the use of intramolecular Diels Alder reactions.Type: GrantFiled: March 12, 2002Date of Patent: January 28, 2003Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Pranab Mishra, Sengen Sun, William V. Murray
-
Patent number: 6509359Abstract: A compound having the formula: wherein all variables are as defined in the specification, for use as a neuramninidase inhibitor.Type: GrantFiled: March 17, 2000Date of Patent: January 21, 2003Inventors: Wayne J. Brouillette, Venkatram Reddy Atigadda, Ming Luo, Yarlagadda S. Babu
-
Patent number: 6420415Abstract: Compounds represented by general formula (1) or salts thereof which have a matrix metalloprotease inhibitory activity and are useful as drugs, wherein the rings A and B represent each an optionally substituted homocycle or heterocycle, etc.; R1s are the same or different and each represents hydrogen, optionally substituted hydrocarbyl, acyl, etc.; X1 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, etc.; X2 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, —O—, etc.; Ys are the same or different represents hydrogen, optionally substituted hydrocarbyl, oxo, etc.; m is 0 or 1; n is an integer of 1 to 3; q1 is an integer of 1 to 2n+4; and q2 is an integer of 0 to 2n+3, provided that q1+q2 is 2n+4.Type: GrantFiled: March 20, 2001Date of Patent: July 16, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Toshiro Yamashita, Hiroshi Nara, Masayuki Takizawa, Koji Yoshimura
-
Patent number: 6392104Abstract: In the presence of an imide compound (e.g., N-hydroxyphthalimide) shown by the formula (2): wherein R1 and R2 independently represents a hydrogen atom, a halogen atom, an alkyl group, an aryl group, a cycloalkyl group; or R1 and R2 may bond together to form a double bond or an aromatic or non-aromatic ring; Y is O or OH and n=1 to 3; or the imide compound and a co-catalyst (e.g., a transition metal compound), an adamantane derivative having a functional group such as a nitro group, an amino group, a hydroxyl group, a carboxyl group, a hydroxymethyl group and an isocyanato group is oxidized with oxygen. According to the above method, an adamantane derivative having a hydroxyl group together with a functional group such as a nitro group, an amino group, a hydroxyl group, a carboxyl group, a hydroxymethyl group and an isocyanato group is efficiently obtained.Type: GrantFiled: November 10, 1998Date of Patent: May 21, 2002Assignee: Daicel Chemical Industries, Ltd.Inventors: Yasutaka Ishii, Tatsuya Nakano, Naruhisa Hirai
-
Publication number: 20020040149Abstract: This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists.Type: ApplicationFiled: November 16, 2001Publication date: April 4, 2002Inventors: Kimberly O. Cameron, HuaZhu Ke, Bruce A. Lefker, David D. Thompson
-
Patent number: 6340751Abstract: Disclosed is a process for the preparation of a 4-substituted azetidinone derivative, which comprises reacting an azetidinone derivative and an amide compound in the presence of a magnesium compound such as those represented by the following formulas (II): and (IV): represented by the following formula (III): MgR5R6 (III) wherein R5 represents a C1-12 alkyl group, a C2-5 alkenyl group, a 5- to 8-membered alicyclic group which may be substituted by a lower C1-4 alkyl group, a phenyl group which may be substituted by a lower C1-4 alkyl group, a lower C1-4 alkoxy group or a halogen atom or a benzyl group which may be substituted by a lower C1-4 alkyl group, a lower C1-4 alkoxy group or a halogen atom, and R6 represents a halogen atom, a methanesulfonyloxy group, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group, a trifluoromethanesulfonyloxy group, an acetoxy group which may be substituted by a halogen atom or a cyano group or an OR7 group (R7 representingType: GrantFiled: July 19, 1999Date of Patent: January 22, 2002Assignee: Takasago International CorporationInventors: Takao Saito, Toshiyuki Murayama, Takaji Matsumoto, Takashi Miura
-
Publication number: 20010047105Abstract: This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists.Type: ApplicationFiled: December 15, 2000Publication date: November 29, 2001Inventors: Kimberly O. Cameron, HuaZhu Ke, Bruce A. Lefker, David D. Thompson
-
Patent number: 6307060Abstract: Disclosed are enantiomerically pure cyclic aminoalcohol esters of arylcycloalkylhydroxycarboxylic acids with at least 90% enantiomeric excess of the (3R,2′R), (3S,2′R), (3R,2′S), or (3S,2′S) configured enantiomer.Type: GrantFiled: May 11, 1999Date of Patent: October 23, 2001Inventors: Christian Noe, Ernst Mutschler, Günter Lambrecht, Michael Elgert, Sittah Czeche, Magali Waelbroeck
-
Patent number: 6294557Abstract: A compound of the following formula: and the salts thereof, wherein A is hydrogen, halo, hydroxy, or the like; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar1 is optionally substituted phenyl or the like; Ar2 is aryl or heteroaryl selected from phenyl, napththyl, pyridyl, and the like, the aryl or heteroaryl being optionally substituted; R1 is hydrogen, hydroxy, C1-C4 alkyl, or the like; and R2 and R3 are independently selected from optionally substituted C1-C7 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, and the like or R2 and R3, together with the nitrogen atom to which they are attached, form an optionally substituted pyrrolidine, piperidine or morpholine ring. These compounds are useful as kappa agonists.Type: GrantFiled: January 26, 2001Date of Patent: September 25, 2001Assignee: Pfizer Inc.Inventors: Fumitaka Ito, Hiroshi Kondo
-
Patent number: 6294568Abstract: The present invention provides compounds represented by the general formula (I): and a salt thereof, and anti-inflammatory agents and antitumor agents containing the compounds as the active ingredients.Type: GrantFiled: June 26, 2000Date of Patent: September 25, 2001Assignee: Nissin Food Products Co., Ltd.Inventors: Toshihiro Yamada, Yoichi Nobuhara, Kazuhiro Kobayashi, Satoshi Hirano, Takanobu Sakurai, Hiroshi Mikami, Ayako Miyake
-
Publication number: 20010012898Abstract: The present invention relates to a method for preparing a chiral ester and more particularly, the method for preparing an optically pure chiral ester from an alkenyl ester at a high yield by mixing and reacting:Type: ApplicationFiled: December 1, 2000Publication date: August 9, 2001Inventors: Jai Wook Park, Mahn-Joo Kim, Jeong Hwan Koh, Hyun Min Jung
-
Patent number: 6262222Abstract: Copolymers containing N-vinyllactam derivatives protected at 3-position are provided and represented by the following formula. The copolymers are used as a photoresist material suitable for deep uv process so that high sensitivity and resolution can be obtained. In addition, ultrafine circuits can be formed and an exceptional improvement in PED stability can be accomplished by use of the photoresist.Type: GrantFiled: October 8, 1998Date of Patent: July 17, 2001Assignee: Hyundai Electronics Industries Co., Ltd.Inventors: Jin Baek Kim, Min Ho Jung, Jong Ho Cheong
-
Patent number: 6172060Abstract: Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NOn-PDE inhibitor where n is 1 or 2. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier. The invention also provides a composition comprising a therapeutically effective amount of an phosphodiesterase inhibitor (PDE inhibitor), which can optionally be substituted with at least one NO or NO2 moiety, and one to ten fold molar excess of a compound that donates, transfers or releases nitrogen monoxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO−), or as the neutral species, nitric oxide (NO•) or which stimulates endogenous EDRF production. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier. The invention also provides methods for treating sexual dysfunctions in males and females.Type: GrantFiled: February 10, 1999Date of Patent: January 9, 2001Assignee: NitroMed, Inc.Inventors: David S. Garvey, Inigo Saenz de Tejada
-
Patent number: 6166036Abstract: Described is an Lp(a) lowering agent or an apo(a) formation suppressing agent, which comprises as an effective ingredient a phenylcarboxylic acid derivative represented by the following formula (1): (wherein, R.sup.1 represents a phenyl group which may have a substituent, A represents a lower alkylene or lower alkyleneoxy group, B represents a methylene or carbonyl group, D represents a lower alkylene group, E represents a lower alkylene or lower alkenylene group, R.sup.2 represents a hydrogen atom or a lower alkyl group and 1, m and n each stands for 0 or 1), or salt thereof. The agent is capable of lowering the blood level of Lp(a) significantly while hardly causing side effects.Type: GrantFiled: October 22, 1999Date of Patent: December 26, 2000Assignee: Taiho Pharmaceutical Co., Ltd.Inventor: Akira Yamamoto
-
Patent number: 6114361Abstract: The present invention relates to a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to pharmaceutical compositions and methods of treatment.Type: GrantFiled: October 29, 1999Date of Patent: September 5, 2000Assignee: Pfizer Inc.Inventors: Ralph P. Robinson, Ellen R. Laird
-
Patent number: 6004994Abstract: The present invention relates to compounds of the formula: ##STR1## and their use in therapeutics, especially as medicaments with anti-inflammatory and analgesic properties.Type: GrantFiled: February 11, 1999Date of Patent: December 21, 1999Assignee: Laboratoires UPSAInventors: Michele Launay, Eric Nicolai, Jean-Marie Teulon
-
Patent number: 5972237Abstract: Heterocyclic compounds IR.sup.1 --X--L (I)whereL is a cyclic carbamate residue, a lactonoxy residue or a lactam residue,X is an oxygen-containing group ##STR1## where A is a linker, and R.sup.1 is an organic radical or a group L,are used as activators for inorganic peroxy compounds, in particular as cold bleach activators or optical brighteners in detergents, cleaners and bleaches and in disinfectants.Type: GrantFiled: November 17, 1997Date of Patent: October 26, 1999Assignee: BASF AktiengesellschaftInventors: Reinhard Muller, Thomas Wehlage, Wolfgang Trieselt, Alfred Oftring, Elisabeth Kappes, Gunter Oetter, Dieter Boeckh, Roland Ettl, Albert Hettche
-
Patent number: 5958821Abstract: A substrate (e.g., a cycloalkane, a polycyclic hydrocarbon, an aromatic compound having a methyl group or methylene group adjacent to an aromatic ring) is oxidized with oxygen in the presence of an oxidation catalyst comprising an imide compound of the following formula (1) (e.g., N-hydroxyphthalimide), and a co-catalyst (except phosphovanadomolybdic acid) containing an element selected from the group consisting of Group 2A elements of the Periodic Table of Elements, transition metals (Group 3A to 7A elements, Group 8 elements, Group 1B elements and Group 2B elements of the Periodic Table of Elements) and Group 3B elements of the Periodic Table of Elements, for the formation of an oxide (e.g., a ketone, an alcohol, a carboxylic acid): ##STR1## wherein R.sup.1 and R.sup.2 represent a substituent such as a hydrogen atom or a halogen atom, or R.sup.1 and R.sup.2 may together form a double bond or an aromatic or nonaromatic 5- to 12-membered ring, X is O or OH, and n is 1 to 3.Type: GrantFiled: September 24, 1997Date of Patent: September 28, 1999Assignee: Daicel Chemical Industries, Ltd.Inventors: Yasutaka Ishii, Tatsuya Nakano
-
Patent number: 5892057Abstract: The salt of a sulfonated succinic acid is cyclized, then converted to novel sulfonated hydroxamic acids by reaction with hydroxylamine (which is added or formed in situ), and the novel hydroxamic acid is then cyclized to the sulfo-N-hydroxysuccinimide salt. This synthetic procedure is simple, direct, and more rapid than present procedures for synthesis of the succinimide. Novel sulfo-hydroxamic acid intermediates are formed during this procedure.Type: GrantFiled: September 18, 1997Date of Patent: April 6, 1999Assignee: Pierce Chemical CompanyInventors: Marty Carey Wilkes, Martin Lee Bremmer
-
Patent number: 5874464Abstract: Conformationally constrained diacylglycerol analogues, pharmaceutical compositions comprising such analogues, and methods of using such analogues as agonists and antagonists of protein kinase C.Type: GrantFiled: January 13, 1995Date of Patent: February 23, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Victor E. Marquez, Jeewoo Lee, Rajiv Sharma, Shaomeng Wang, George W. A. Milne, Marc C. Nicklaus, Peter M. Blumberg, Nancy E. Lewin
-
Patent number: 5846907Abstract: Pyrazol-4-ylbenzoyl compounds of the formula I ##STR1## where Z is a 5- or 6-membered heterocyclic saturated or unsaturated radical, Q is a pyrazole ring and L and M are as defined in the specification, their use as herbicidal compounds and to processes for preparing the compounds.Type: GrantFiled: July 30, 1997Date of Patent: December 8, 1998Assignee: BASF AktiengesellschaftInventors: Wolfgang von Deyn, Regina Luise Hill, Uwe Kardorff, Stefan Engel, Martina Otten, Marcus Vossen, Peter Plath, Harald Rang, Albrecht Harreus, Hartmann Konig, Helmut Walter, Karl-Otto Westphalen, Ulf Misslizt
-
Patent number: 5846906Abstract: Herbicidally active phenyldiketone compounds of the formula I ##STR1## in which the substituents have the following meanings: L and M are hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, C.sub.1 -C.sub.4 -alkoxy, it being possible for these groups to be unsubstituted or substituted by one to five halogen atoms or C.sub.1 -C.sub.4 -alkoxy, or halogen, cyano, nitro, a group --(Y).sub.n --S(O).sub.m R.sup.7 or a group --(Y).sub.n --CO--R.sup.8,Z is a 5- or 6-membered heterocyclic saturated or unsaturated radical which has one to three hetero atoms selected from the group consisting of oxygen, sulfur or nitrogen and which is unsubstituted or substituted by halogen, cyano, nitro, a group --CO--R.sup.8, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.3 -C.sub.8 -cycloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy, C.sub.1 -C.sub.4 -alkylthio, C.sub.1 -C.sub.4 -haloalkylthio, di-C.sub.1 -C.sub.Type: GrantFiled: July 30, 1997Date of Patent: December 8, 1998Assignee: BASF AktiengesellschaftInventors: Wolfgang von Deyn, Regina Luise Hill, Uwe Kardorff, Stefan Engel, Martina Otten, Marcus Vossen, Peter Plath, Harald Rang, Albrecht Harreus, Hartmann Konig, Helmut Walter, Karl-Otto Westphalen, Ulf Misslitz
-
Patent number: 5837867Abstract: The present invention is directed to the use of cyclic amide alkoxylate compounds as additives in fuel compositions having a major amount of a mixture of hydrocarbons in the gasoline boiling range and a minor amount of one or more cyclic amide alkoxylate compounds of the formula: ##STR1## wherein x is from 2 to 20 and y is from 1 to 50. R.sub.1 and R.sub.2 are independently hydrogen or hydrocarbyl of 1 to 100 carbon atoms. R.sub.3 is hydrocarbyl of 1 to 100 carbon atoms and R.sub.4 is independently hydrocarbyl of 2 to 100 carbon atoms. R.sub.5 is hydrogen, hydrocarbyl of 1 to 100 carbon atoms or acyl of 1 to 20 carbon atoms.The invention is also directed to the use of these cyclic amide alkoxylate compounds for decreasing intake valve deposits, controlling octane requirement increases and reducing octane requirement. The invention is further directed to novel cyclic amide alkoxylate compounds.Type: GrantFiled: August 6, 1996Date of Patent: November 17, 1998Assignee: Shell Oil CompanyInventors: Jiang-Jen Lin, Charles Lee Edwards, Pen-Chung Wang, Garo Garbis Vaporciyan
-
Patent number: 5756762Abstract: The present invention relates to a novel enantiospecific processes for preparing (S)-4-amino-hepta-5,6-dienoic acid and pharmaceutically acceptable salts thereof, which is useful as an irreversible inhibitor of GABA-T, to novel intermediates thereof, and a process for preparing an intermediate thereof.Type: GrantFiled: January 9, 1997Date of Patent: May 26, 1998Assignee: Merrell Pharmaceuticals Inc.Inventor: H. Michael Kolb
-
Patent number: 5750680Abstract: N-vinyllactam derivatives protected at the 3-position are provided and represented by the following formula (I). These are polymerized into homo- and copolymers for use in microlithography of semiconductor manufacture. The polymers are used as a photoresist material suitable for a deep UV process so that pictures of high sensitivity and high resolution can be obtained. In addition, ultrafine circuits can be formed and an exceptional improvement in pattern formation can be accomplished through the use of the photoresist of the invention.Type: GrantFiled: September 12, 1996Date of Patent: May 12, 1998Assignees: Hyundai Electronics Industries Co., Ltd., Korea Advanced Institute of Science & TechnologyInventors: Jin Baek Kim, Min Ho Jung, Kyeong Ho Chang
-
Patent number: 5675019Abstract: A process of preparing lactam derivatives of pilocarpine is disclosed. The process involves condensation of a dihydroxybutene and alkyl orthoester to form a lactone intermediate which is oxidized to trans-pilopic acid. This lactone ring is reacted with a benzylamine and the benzyl group removed with a novel dissolving metal reduction mixture to yield the key intermediate IV ##STR1## which can be elaborated to pilolactam through a known sequence of steps.Type: GrantFiled: July 18, 1996Date of Patent: October 7, 1997Assignee: AllerganInventors: Lloyd J. Dolby, Nestor A. Fedoruk, Shervin Esfandiari, Michael E. Garst
-
Patent number: 5674811Abstract: A cyanoketone derivatives of the following formula (1) ##STR1## which are characterized by excellent herbicidal activity and effectiveness against a variety of broad leafed weeds, including barnyard grass, green foxtail, velvet leaf, livid amaranth and hairy beggar ticks.Type: GrantFiled: October 6, 1994Date of Patent: October 7, 1997Assignee: Tokuyama CorporationInventors: Toshio Kitajima, Tadashi Kobutani, Shozo Kato, Masao Yamaguchi, Masahiko Ishizaki, deceased
-
Patent number: 5629265Abstract: Disclosed herein are cyanoketone derivatives of the following formula (1) ##STR1## such as 1-cyano-1-piperidinocarbonyl-3-[4-(2-chloro-4-trifluoromethylphenoxy)pheno xy]-2-butanone, 1-cyano-1-piperidinocarbonyl-3-[4-(3-chloro-5-trifluoromethyl-2-pyridyloxy )phenoxy]-2-butanone, 1-cyano-1-(N-methyl-N-dichlorophenyl)aminocarbonyl-3-[4-(2-quinoxalyloxy)p henoxy]-2-butanone, 1-cyano-1-(N,N-dibutyl)aminocarbonyl-3-[4-(3-chloro-5-trifluoromethyl-2-py ridyloxy)phenoxy-2-butanone, and the like, which are characterized by excellent herbicidal activity and effectiveness against a variety of gramineous weeds.Type: GrantFiled: June 22, 1994Date of Patent: May 13, 1997Assignee: Tokuyama CorporationInventors: Masahiko Ishizaki, Seiji Nagata, Junji Takenaka
-
Patent number: 5614638Abstract: New nonionic radiographic contrast agents having the formula ##STR1## wherein Y is a single bond, --CH.sub.2 CH.sub.2 --, --CH.sub.2 O--, --OCH.sub.2 --, ##STR2## --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --O-- or ##STR3## R.sub.1, R.sub.1 ' and R.sub.2 are the same or different and are hydrogen, alkyl or hydroxyalkyl.Hydroxyalkyl refers to such alkyl groups having 1 or more hydroxy groups. Preferred hydroxyalkyl groups include: ##STR4## R.sub.3 and R.sub.4 are the same or different and are hydrogen, methyl or --CH.sub.2 CH.sub.2 OH; R.sub.5 is hydrogen, alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH or OH and R.sub.6 is alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH, OH or hydrogen and may be the same or different than R.sub.5 and m is zero or one, with the proviso that no methylene or methine carbon atom of the heterocyclic ring is attached to both a nitrogen and an oxygen atom with the additional proviso that when Y is a single bond, m is not zero.Type: GrantFiled: June 5, 1992Date of Patent: March 25, 1997Assignee: Bracco International B.V.Inventors: Ramachandran S. Ranganathan, Thangavel Arunchalam, Edmund R. Marinelli, Radhakrishna K. Pillai
-
Patent number: 5605925Abstract: There are disclosed 1-aminoacetamidopyrroles and 1-amino-2-(substituted)pyrroles and related compounds of the formula ##STR1## wherein all substituents are defined herein, which are useful as glycine partial agonists and for the enhancement of learning and memory and for the treatment of memory dysfunctions associated with neurodegenerative disorders and are thus indicated in the treatment of Alzheimer's disease and other senile dementias.Type: GrantFiled: November 7, 1994Date of Patent: February 25, 1997Assignee: Hoechst Marion Roussel, Inc.Inventors: Lawrence L. Martin, Raymond W. Kosley, Jr., Denise M. Flanagan, Gert U. Kuerzel, Peter A. Nemoto, David G. Wettlaufer
-
Patent number: 5591769Abstract: The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.Type: GrantFiled: June 1, 1995Date of Patent: January 7, 1997Assignee: Karl Thomae GmbHInventors: Frank Himmelsbach, Volkhard Austel, Helmut Pieper, Wolfgang Eisert, Thomas Mueller, Johannes Weisenberger, Guenter Linz, Gerd Krueger
-
Patent number: 5580999Abstract: Novel alcohols of the formula ##STR1## wherein R.sup.a is azido or phthalimido, R.sup.4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, R.sup.7 and R.sup.8 together are a trimethylene or tetramethylene group which is optionally substituted by hydroxy, alkoxycarbonylamino or acylamino or in which one --CH.sub.2 -- group is replaced by --NH--, -N(alkoxycarbonyl)-,-N(acyl)- or --S--or which carries a fused cycloalkane, aromatic or heteroaromatic ring, and R.sup.9 is alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula ##STR2## in which R.sup.10 and R.sup.11 each is alkyl, are described along with a process for their manufacture. These alcohols are useful as intermediates, for example in the manufacture of amino acid derivatives having antiviral activity.Type: GrantFiled: May 12, 1995Date of Patent: December 3, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Kevin E. B. Parkes, Sally Redshaw, Gareth J. Thomas